Functional Dyspepsia

This chapter provides definition of functional dyspepsia (FD), evaluation, and diagnostic tests, methodology of clinical treatment trials with a focus on outcome measures used to determine the efficacy of treatments, and treatments including antacids, H 2 ‐receptor antagonists (H 2 ‐RAs), proton pum...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
1. Verfasser: Zanten, Sander Veldhuyzen
Format: Buchkapitel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 138
container_issue
container_start_page 127
container_title
container_volume
creator Zanten, Sander Veldhuyzen
description This chapter provides definition of functional dyspepsia (FD), evaluation, and diagnostic tests, methodology of clinical treatment trials with a focus on outcome measures used to determine the efficacy of treatments, and treatments including antacids, H 2 ‐receptor antagonists (H 2 ‐RAs), proton pump inhibitors (PPIs), prokinetic agents, anti‐Helicobacter therapy, antidepressant therapy, and psychological interventions. A problem in every day management of FD is that primary care physicians do not readily make a distinction between gastroesophageal reflux disease (GERD) and dyspepsia, as in both instances the most likely pharmacological therapy is to prescribe a PPI. Dividing FD into subgroups has become popular despite evidence of the existence of considerable overlap among them. The ROME II classification recognized four subgroups: ulcer‐like dyspepsia, reflux‐like dyspepsia, dysmotility‐like dyspepsia, and unclassified dyspepsia. The chapter summarizes the suggested treatment algorithm for FD. The evidence for use of tricyclic antidepressants, especially amitriptyline, is getting stronger and this also true for cognitive behavioral therapy.
doi_str_mv 10.1002/9781119211419.ch8
format Book Chapter
fullrecord <record><control><sourceid>wiley</sourceid><recordid>TN_cdi_wiley_ebooks_10_1002_9781119211419_ch8_ch8</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10.1002/9781119211419.ch8</sourcerecordid><originalsourceid>FETCH-LOGICAL-s150f-bfdd66d7150002e18bd95fe44a8cdc21ccc1b03a398bf332ca84644d02974f7f3</originalsourceid><addsrcrecordid>eNptkE9LAzEQxSNSUGtvXrz5BbbOJOlOcpTaVqHQSz2H_KWrS3chitRPbxalUPEwDG94vwdvGLtFmCIAv9ekEFFzRIl66nfqjF0dD3R-FELRBZvk_AqFQiAifclulh97_950e9vePR5yH_vc2Gs2SrbNcfK7x-xludjOn6r1ZvU8f1hXGWeQKpdCqOtARZTEiMoFPUtRSqt88By99-hAWKGVS0Jwb5WspQzANclESYxZ9ZP72bTxYKLrurdsTvqYr6Y3pZPpw-DHf_wIZvjDH25gyohvYpFObQ</addsrcrecordid><sourcetype>Enrichment Source</sourcetype><iscdi>true</iscdi><recordtype>book_chapter</recordtype></control><display><type>book_chapter</type><title>Functional Dyspepsia</title><source>eBooks on EBSCOhost</source><creator>Zanten, Sander Veldhuyzen</creator><contributor>Feagan, Brian G ; McDonald, John W D ; Kahrilas, Peter J ; Jalan, Rajiv</contributor><creatorcontrib>Zanten, Sander Veldhuyzen ; Feagan, Brian G ; McDonald, John W D ; Kahrilas, Peter J ; Jalan, Rajiv</creatorcontrib><description>This chapter provides definition of functional dyspepsia (FD), evaluation, and diagnostic tests, methodology of clinical treatment trials with a focus on outcome measures used to determine the efficacy of treatments, and treatments including antacids, H 2 ‐receptor antagonists (H 2 ‐RAs), proton pump inhibitors (PPIs), prokinetic agents, anti‐Helicobacter therapy, antidepressant therapy, and psychological interventions. A problem in every day management of FD is that primary care physicians do not readily make a distinction between gastroesophageal reflux disease (GERD) and dyspepsia, as in both instances the most likely pharmacological therapy is to prescribe a PPI. Dividing FD into subgroups has become popular despite evidence of the existence of considerable overlap among them. The ROME II classification recognized four subgroups: ulcer‐like dyspepsia, reflux‐like dyspepsia, dysmotility‐like dyspepsia, and unclassified dyspepsia. The chapter summarizes the suggested treatment algorithm for FD. The evidence for use of tricyclic antidepressants, especially amitriptyline, is getting stronger and this also true for cognitive behavioral therapy.</description><identifier>ISBN: 1119211387</identifier><identifier>ISBN: 9781119211389</identifier><identifier>EISBN: 1119211417</identifier><identifier>EISBN: 9781119211419</identifier><identifier>DOI: 10.1002/9781119211419.ch8</identifier><language>eng</language><publisher>Chichester, UK: John Wiley &amp; Sons, Ltd</publisher><subject>anti‐Helicobacter therapy ; cognitive behavioral therapy ; functional dyspepsia ; gastroesophageal reflux disease ; prokinetic agents ; proton pump inhibitors ; ROME II classification ; tricyclic antidepressants</subject><ispartof>Evidence‐based Gastroenterology and Hepatology 4e, 2019, p.127-138</ispartof><rights>Copyright © 2019 John Wiley &amp; Sons, Ltd. All rights reserved.</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>775,776,780,789,27902</link.rule.ids></links><search><contributor>Feagan, Brian G</contributor><contributor>McDonald, John W D</contributor><contributor>Kahrilas, Peter J</contributor><contributor>Jalan, Rajiv</contributor><creatorcontrib>Zanten, Sander Veldhuyzen</creatorcontrib><title>Functional Dyspepsia</title><title>Evidence‐based Gastroenterology and Hepatology 4e</title><description>This chapter provides definition of functional dyspepsia (FD), evaluation, and diagnostic tests, methodology of clinical treatment trials with a focus on outcome measures used to determine the efficacy of treatments, and treatments including antacids, H 2 ‐receptor antagonists (H 2 ‐RAs), proton pump inhibitors (PPIs), prokinetic agents, anti‐Helicobacter therapy, antidepressant therapy, and psychological interventions. A problem in every day management of FD is that primary care physicians do not readily make a distinction between gastroesophageal reflux disease (GERD) and dyspepsia, as in both instances the most likely pharmacological therapy is to prescribe a PPI. Dividing FD into subgroups has become popular despite evidence of the existence of considerable overlap among them. The ROME II classification recognized four subgroups: ulcer‐like dyspepsia, reflux‐like dyspepsia, dysmotility‐like dyspepsia, and unclassified dyspepsia. The chapter summarizes the suggested treatment algorithm for FD. The evidence for use of tricyclic antidepressants, especially amitriptyline, is getting stronger and this also true for cognitive behavioral therapy.</description><subject>anti‐Helicobacter therapy</subject><subject>cognitive behavioral therapy</subject><subject>functional dyspepsia</subject><subject>gastroesophageal reflux disease</subject><subject>prokinetic agents</subject><subject>proton pump inhibitors</subject><subject>ROME II classification</subject><subject>tricyclic antidepressants</subject><isbn>1119211387</isbn><isbn>9781119211389</isbn><isbn>1119211417</isbn><isbn>9781119211419</isbn><fulltext>true</fulltext><rsrctype>book_chapter</rsrctype><creationdate>2019</creationdate><recordtype>book_chapter</recordtype><sourceid/><recordid>eNptkE9LAzEQxSNSUGtvXrz5BbbOJOlOcpTaVqHQSz2H_KWrS3chitRPbxalUPEwDG94vwdvGLtFmCIAv9ekEFFzRIl66nfqjF0dD3R-FELRBZvk_AqFQiAifclulh97_950e9vePR5yH_vc2Gs2SrbNcfK7x-xludjOn6r1ZvU8f1hXGWeQKpdCqOtARZTEiMoFPUtRSqt88By99-hAWKGVS0Jwb5WspQzANclESYxZ9ZP72bTxYKLrurdsTvqYr6Y3pZPpw-DHf_wIZvjDH25gyohvYpFObQ</recordid><startdate>20190423</startdate><enddate>20190423</enddate><creator>Zanten, Sander Veldhuyzen</creator><general>John Wiley &amp; Sons, Ltd</general><scope/></search><sort><creationdate>20190423</creationdate><title>Functional Dyspepsia</title><author>Zanten, Sander Veldhuyzen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-s150f-bfdd66d7150002e18bd95fe44a8cdc21ccc1b03a398bf332ca84644d02974f7f3</frbrgroupid><rsrctype>book_chapters</rsrctype><prefilter>book_chapters</prefilter><language>eng</language><creationdate>2019</creationdate><topic>anti‐Helicobacter therapy</topic><topic>cognitive behavioral therapy</topic><topic>functional dyspepsia</topic><topic>gastroesophageal reflux disease</topic><topic>prokinetic agents</topic><topic>proton pump inhibitors</topic><topic>ROME II classification</topic><topic>tricyclic antidepressants</topic><toplevel>online_resources</toplevel><creatorcontrib>Zanten, Sander Veldhuyzen</creatorcontrib></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zanten, Sander Veldhuyzen</au><au>Feagan, Brian G</au><au>McDonald, John W D</au><au>Kahrilas, Peter J</au><au>Jalan, Rajiv</au><format>book</format><genre>bookitem</genre><ristype>CHAP</ristype><atitle>Functional Dyspepsia</atitle><btitle>Evidence‐based Gastroenterology and Hepatology 4e</btitle><date>2019-04-23</date><risdate>2019</risdate><spage>127</spage><epage>138</epage><pages>127-138</pages><isbn>1119211387</isbn><isbn>9781119211389</isbn><eisbn>1119211417</eisbn><eisbn>9781119211419</eisbn><abstract>This chapter provides definition of functional dyspepsia (FD), evaluation, and diagnostic tests, methodology of clinical treatment trials with a focus on outcome measures used to determine the efficacy of treatments, and treatments including antacids, H 2 ‐receptor antagonists (H 2 ‐RAs), proton pump inhibitors (PPIs), prokinetic agents, anti‐Helicobacter therapy, antidepressant therapy, and psychological interventions. A problem in every day management of FD is that primary care physicians do not readily make a distinction between gastroesophageal reflux disease (GERD) and dyspepsia, as in both instances the most likely pharmacological therapy is to prescribe a PPI. Dividing FD into subgroups has become popular despite evidence of the existence of considerable overlap among them. The ROME II classification recognized four subgroups: ulcer‐like dyspepsia, reflux‐like dyspepsia, dysmotility‐like dyspepsia, and unclassified dyspepsia. The chapter summarizes the suggested treatment algorithm for FD. The evidence for use of tricyclic antidepressants, especially amitriptyline, is getting stronger and this also true for cognitive behavioral therapy.</abstract><cop>Chichester, UK</cop><pub>John Wiley &amp; Sons, Ltd</pub><doi>10.1002/9781119211419.ch8</doi><tpages>12</tpages></addata></record>
fulltext fulltext
identifier ISBN: 1119211387
ispartof Evidence‐based Gastroenterology and Hepatology 4e, 2019, p.127-138
issn
language eng
recordid cdi_wiley_ebooks_10_1002_9781119211419_ch8_ch8
source eBooks on EBSCOhost
subjects anti‐Helicobacter therapy
cognitive behavioral therapy
functional dyspepsia
gastroesophageal reflux disease
prokinetic agents
proton pump inhibitors
ROME II classification
tricyclic antidepressants
title Functional Dyspepsia
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T23%3A59%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley&rft_val_fmt=info:ofi/fmt:kev:mtx:book&rft.genre=bookitem&rft.atitle=Functional%20Dyspepsia&rft.btitle=Evidence%E2%80%90based%20Gastroenterology%20and%20Hepatology%204e&rft.au=Zanten,%20Sander%20Veldhuyzen&rft.date=2019-04-23&rft.spage=127&rft.epage=138&rft.pages=127-138&rft.isbn=1119211387&rft.isbn_list=9781119211389&rft_id=info:doi/10.1002/9781119211419.ch8&rft_dat=%3Cwiley%3E10.1002/9781119211419.ch8%3C/wiley%3E%3Curl%3E%3C/url%3E&rft.eisbn=1119211417&rft.eisbn_list=9781119211419&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true